[go: up one dir, main page]

NO995928L - Alfa-1-antitrypsin-preparater samt fremgangsmåte ved fremstilling derav - Google Patents

Alfa-1-antitrypsin-preparater samt fremgangsmåte ved fremstilling derav

Info

Publication number
NO995928L
NO995928L NO995928A NO995928A NO995928L NO 995928 L NO995928 L NO 995928L NO 995928 A NO995928 A NO 995928A NO 995928 A NO995928 A NO 995928A NO 995928 L NO995928 L NO 995928L
Authority
NO
Norway
Prior art keywords
preparation
antitrypsin
preparations
alpha
inactive
Prior art date
Application number
NO995928A
Other languages
English (en)
Other versions
NO995928D0 (no
Inventor
Erwin Mattes
Peter H Matthiessen
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Ag filed Critical Baxter Ag
Publication of NO995928D0 publication Critical patent/NO995928D0/no
Publication of NO995928L publication Critical patent/NO995928L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Det er beskrevet et naturlig, kromatografisk ren- set al-AT-preparat som har en renhet på minst 0,7 PE/mg protein og en relativ plasma-al-AT-aktivitet på minst 120 %. Forholdet mellom aktivt og inak- tivt al-AT er større enn i plasma. Dessuten er det beskrevet en fremgangsmåte ved fremstilling av dette preparat samt anvendelsen av et bærermateriale, f.eks. et uorgangisk basrermate- riale, såsom hydroksyapatitt, for å skille aktivt al-AT fra inaktivt al-AT.
NO995928A 1997-06-10 1999-12-03 Alfa-1-antitrypsin-preparater samt fremgangsmåte ved fremstilling derav NO995928L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0100797A AT407114B (de) 1997-06-10 1997-06-10 Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
PCT/AT1998/000130 WO1998056821A1 (de) 1997-06-10 1998-05-20 Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung

Publications (2)

Publication Number Publication Date
NO995928D0 NO995928D0 (no) 1999-12-03
NO995928L true NO995928L (no) 2000-02-09

Family

ID=3504791

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995928A NO995928L (no) 1997-06-10 1999-12-03 Alfa-1-antitrypsin-preparater samt fremgangsmåte ved fremstilling derav

Country Status (15)

Country Link
US (1) US6974792B2 (no)
EP (1) EP0991666B1 (no)
JP (1) JP2002510294A (no)
AT (1) AT407114B (no)
AU (1) AU729389B2 (no)
BR (1) BR9810002A (no)
CA (1) CA2293806C (no)
DE (1) DE59814132D1 (no)
DK (1) DK0991666T3 (no)
ES (1) ES2296334T3 (no)
HU (1) HUP0003712A1 (no)
NO (1) NO995928L (no)
PT (1) PT991666E (no)
SK (1) SK171699A3 (no)
WO (1) WO1998056821A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3731400A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
US7777006B2 (en) 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
AU2015200572B2 (en) * 2002-12-31 2016-06-02 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
AU2012203030B2 (en) * 2002-12-31 2015-02-19 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
UA86775C2 (ru) * 2003-08-12 2009-05-25 Октафарма Аг Способ очистки раствора альфа-1-антитрипсина
WO2005019434A2 (en) 2003-08-26 2005-03-03 The Regents Of The University Of Colorado, A Body Corporate Serine protease inhibitors for treatment of bacterial infections
SI1664123T2 (sl) * 2003-09-22 2012-03-30 Kamada Ltd Priprava inhibitorja alfa proteinaze v velikem merilu in njegova uporaba
GB0524432D0 (en) * 2005-11-30 2006-01-11 Nhs Blood & Transplant Method
DK1999262T3 (da) * 2006-03-30 2012-10-22 Baxter Int Fremgangsmåde til rensning af rekombinant alfa 1-antitrypsin omfattende et anionbytterchromatografitrin
EP2066174B1 (en) 2006-09-12 2017-11-08 Beth Israel Deaconess Medical Center, Inc. Compositions containing alpha-1-antitrypsin and methods for use
US8436152B2 (en) 2007-08-17 2013-05-07 Csl Behring Gmbh Methods for purification of alpha-1-antitrypsin andapolipoprotein A-1
WO2009059082A2 (en) * 2007-11-02 2009-05-07 Talecris Biotherapeutics, Inc. Method, composition, and article of manufacture for providing alpha-1 antitrypsin
NZ599783A (en) 2009-11-03 2013-10-25 Grifols Therapeutics Inc Composition and use for alpha-1 proteinase inhibitor
PT2503995T (pt) 2009-11-24 2017-11-23 Grifols Therapeutics Inc Métodos de liofilização, composições e kits
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US10094034B2 (en) 2015-08-28 2018-10-09 Lam Research Corporation Edge flow element for electroplating apparatus
US10233556B2 (en) 2010-07-02 2019-03-19 Lam Research Corporation Dynamic modulation of cross flow manifold during electroplating
MX351189B (es) 2011-12-30 2017-10-04 Grifols Sa Inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares.
CN103788209B (zh) * 2012-10-29 2016-02-24 广东双林生物制药有限公司 一种α1-蛋白酶抑制剂的制备方法
WO2014160768A1 (en) 2013-03-29 2014-10-02 The Regents Of The University Of Colorado Compositions and methods for preparing a subject for organ or non-organ implantation
US10364505B2 (en) 2016-05-24 2019-07-30 Lam Research Corporation Dynamic modulation of cross flow manifold during elecroplating

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4439358A (en) * 1982-06-17 1984-03-27 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US4697003A (en) * 1985-11-01 1987-09-29 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US6284874B1 (en) * 1994-06-17 2001-09-04 Alpha Therapeutic Corporation Process for separating α1-proteinase inhibitor from cohn fraction IV1 and IV4 paste
US5610285A (en) * 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
US5760179A (en) * 1996-06-10 1998-06-02 Desmos, Inc. Purification of soluble laminin 5

Also Published As

Publication number Publication date
BR9810002A (pt) 2000-08-01
AU729389B2 (en) 2001-02-01
ES2296334T3 (es) 2008-04-16
EP0991666A1 (de) 2000-04-12
SK171699A3 (en) 2000-06-12
WO1998056821A1 (de) 1998-12-17
DE59814132D1 (de) 2008-01-10
CA2293806C (en) 2010-02-09
US20020082214A1 (en) 2002-06-27
AT407114B (de) 2000-12-27
JP2002510294A (ja) 2002-04-02
HUP0003712A1 (hu) 2001-02-28
DK0991666T3 (da) 2008-04-14
ATA100797A (de) 2000-05-15
AU7418098A (en) 1998-12-30
EP0991666B1 (de) 2007-11-28
CA2293806A1 (en) 1998-12-17
US6974792B2 (en) 2005-12-13
PT991666E (pt) 2007-12-27
NO995928D0 (no) 1999-12-03

Similar Documents

Publication Publication Date Title
NO995928L (no) Alfa-1-antitrypsin-preparater samt fremgangsmåte ved fremstilling derav
NO954342L (no) Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav
BG102259A (en) Compostions with controlled paroxetine release
AU5242000A (en) Nematicidal trifluorobutenes
MX9702865A (es) Agentes estrogenicos.
NO20061455L (no) 2,6 dioksopiperidin samt farmasoytiske preparater som inneholder disse
AU1750097A (en) Highly concentrated, lyophilized, and liquid factor ix formulations
MY116535A (en) New stable pharmaceutical preparation for producing propellant gas-free aerosols
JO2034B1 (en) Isotopes of the hormone peptide its uses and the chemical compounds it contains
BG104130A (en) Aqueous aerosol forms containing biologically active macromolecules, and method for the preparation of the respective aerosols
BG104315A (en) Prostaglandine agonists and their application for the treatment of osteal diseases
HUP0003314A2 (hu) GLP-1 analógok és származékok alkalmazása elhízás szabályozására használható gyógyszerkészítmények előállítására
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
AU3126600A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
TR200200785T2 (tr) 8-Fenil-6,9-dihidro-[1,2,4] triazolo [3,4-i] purin-5-on türevleri
GB0011203D0 (en) Chemical compounds
IL114294A0 (en) Sterol derivatives
ITFI920078A0 (it) Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umana.
BG102660A (en) Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
AU7525398A (en) Inhibitors for urokinase receptor
CA2218643A1 (en) Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
MY118946A (en) Novel intermediates and their use to prepare n, n''- bridged bisindolylmaleimides

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application